December 24, 2024
5 min watch
Save
VIDEO: Bruton tyrosine kinase inhibitor studied in immune thrombocytopenia
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of the Bruton tyrosine kinase inhibitor rilzabrutinib in patients with immune thrombocytopenic purpura.
Mistry, an assistant professor at University of Pennsylvania, highlighted the phase 3 LUNA-3 study, which compared rilzabrutinib (Sanofi) to a placebo in an effort to measure the durability of response.
“I’m excited to see this drug potentially on the market in the near future, just to continue to give our patients more options for ITP management,” Mistry said.
Reference:
- Kuter DJ, et al. Abstract 5. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Mistry reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.